|
| The role of angiogenesis in diabetic heart failure:a potential target for Chinese medicine in the treatment of diabetic cardiomyopathy |
| Hits 774 Download times 752 Received:October 22, 2022 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2023.01.21 |
| Key Words
diabetic cardiomyopathy;heart failure;angiogenesis;traditional Chinese medicine;blood activation;pharmacotherapy |
| Author Name | Affiliation | E-mail | | CHEN Zihao | Tianjin University of Traditional Chinese Medicine, State Key Laboratory of Component Chinese Medicines, Tianjin 301617, China
Tianjin International Joint Institute of Biomedicine, Center for New Drug Development in Traditional Chinese Medicine, Tianjin 300457, China | | | HE Shuang | Tianjin University of Traditional Chinese Medicine, State Key Laboratory of Component Chinese Medicines, Tianjin 301617, China
Tianjin International Joint Institute of Biomedicine, Center for New Drug Development in Traditional Chinese Medicine, Tianjin 300457, China | | | ZHAO Fangzhe | Tianjin University of Traditional Chinese Medicine, State Key Laboratory of Component Chinese Medicines, Tianjin 301617, China
Tianjin International Joint Institute of Biomedicine, Center for New Drug Development in Traditional Chinese Medicine, Tianjin 300457, China | | | FAN Siwen | Tianjin University of Traditional Chinese Medicine, State Key Laboratory of Component Chinese Medicines, Tianjin 301617, China
Tianjin International Joint Institute of Biomedicine, Center for New Drug Development in Traditional Chinese Medicine, Tianjin 300457, China | | | ZHANG Lei | Tianjin University of Traditional Chinese Medicine, State Key Laboratory of Component Chinese Medicines, Tianjin 301617, China
Tianjin International Joint Institute of Biomedicine, Center for New Drug Development in Traditional Chinese Medicine, Tianjin 300457, China | | | YANG Xinyue | Tianjin University of Traditional Chinese Medicine, State Key Laboratory of Component Chinese Medicines, Tianjin 301617, China
Tianjin International Joint Institute of Biomedicine, Center for New Drug Development in Traditional Chinese Medicine, Tianjin 300457, China | | | LI Shan | Tianjin University of Traditional Chinese Medicine, State Key Laboratory of Component Chinese Medicines, Tianjin 301617, China
Tianjin International Joint Institute of Biomedicine, Center for New Drug Development in Traditional Chinese Medicine, Tianjin 300457, China | | | ZHU Yan | Tianjin University of Traditional Chinese Medicine, State Key Laboratory of Component Chinese Medicines, Tianjin 301617, China
Tianjin International Joint Institute of Biomedicine, Center for New Drug Development in Traditional Chinese Medicine, Tianjin 300457, China | yanzhu.harvard@icloud.com |
|
| Abstract
|
| There is strong clinical evidence that diabetes mellitus is closely associated with an increased risk of heart failure. Diabetes exacerbates diastolic and systolic heart failure after myocardial infarction,triggers an idiosyncratic myocardial microvascular complication,diabetic cardiomyopathy. New advances in biomedicine have revealed complex links and mechanisms of action between diabetes and cardiovascular abnormalities,including energy metabolism,glycaemic control and angiogenesis. Traditional Chinese medicine(TCM),based on a holistic view and dialectical theory of treatment,has a long history in the management of diabetes and its complications. This review uses bioresponse signalling network analysis to identify potential therapeutic targets for the treatment of diabetic heart failure through modulation of angiogenesis,and summarises some basic research related to TCM commonly used in the treatment of diabetes and heart failure. These drugs were found to be important components of proprietary TCM for the treatment of diabetic heart failure,and the active ingredients could act on some of the potential therapeutic targets identified by the bioresponse signalling network analysis,thus illustrating the feasibility of TCM for the treatment of diabetic heart failure through modulation of angiogenesis and providing some evidence to support the clinical reference application. |
|
|
|
|
|
